On the Horizon: HER3-Targeted Antibody-Drug Conjugates for Advanced Solid Tumors An Infographic-Enhanced Journal Club Activity - Rationale and Mechanism of Action of HER3-Targeted ADCs for Advanced NSCLC and Breast Cancer
hosted byParadigm Medical Communications, LLCOn the Horizon: HER3-Targeted Antibody-Drug Conjugates for Advanced Solid Tumors An Infographic-Enhanced Journal Club Activity - Rationale and Mechanism of Action of HER3-Targeted ADCs for Advanced NSCLC and Breast Cancer is organized by Paradigm Medical Communications, LLC.
Release Date: July 29, 2022
Expiration Date: January 29, 2024
Program Overview:
Although treatments for advanced non-small cell lung cancer (NSCLC) and breast cancer are rapidly advancing, these diseases remain incurable. Antibody-drug conjugates (ADCs) offer a novel approach to targeting HER3 as a method of delivering a cytotoxic payload that eliminates tumor cells. This infographic provides an overview of HER3-targeted ADCs, including expert commentary from oncology clinicians, to ensure healthcare professionals are up to date regarding advances in treatments for NSCLC and breast cancer.
Learning Objectives:
Upon completion of this activity, participants should be able to:
• Describe the rationale for targeting HER3 in solid tumors, particularly epidermal growth factor receptor (EGFR)-mutated NSCLCs and HER3-expressing breast cancers
• Summarize the latest data from ongoing clinical trials of ADCs that target HER3 for the treatment of advanced solid tumors
